Shots:
- Imvax has reported the topline data from the P-IIb trial assessing IGV-001 vs PBO in 99 pts with newly diagnosed glioblastoma (ndGBM)
- Trial showed an mOS of 20.3 vs 14mos., with an mFU of 22mos. for all pts, plus IGV-001 demonstrated measurable patient benefit across various metrics; safety was consistent with previous studies
- Additionally, Imvax plans to request an FDA meeting to discuss the regulatory path for IGV-001, an autologous biologic-device candidate derived from the Goldspire immuno-oncology platform for solid cancers
Ref: Businesswire | Image: Imvax | Press Release
Related News: Belite Bio Reports Topline P-III (DRAGON) Trial Data on Tinlarebant for Stargardt Disease Type 1 (STGD1)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
